NCT06867913 - A Study of Selenomethionine and Myo-inositol(SOLOWAYS_TM) in Patients With Autoimmune Thyroiditis Carrying the DIO2 Thr92Ala Polymorphism | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 15, 2024

Primary Completion Date

December 26, 2024

Study Completion Date

February 21, 2025

Conditions

Autoimmune Thyroiditis

Interventions

DIETARY_SUPPLEMENT

Supplement groupx

"Selenomethionine (e.g., 100 µg/day)~* Myo-inositol (e.g., 600 mg/day or higher)~* Patients on levothyroxine will maintain their current dose (if clinically indicated)."

DIETARY_SUPPLEMENT

Supplement groupx

"Selenomethionine (e.g., 100 µg/day)~* Myo-inositol (e.g., 600 mg/day or higher)~* Patients on levothyroxine will maintain their current dose (if clinically indicated)."

Trial Locations (1)

630090

Center for New Medical Technologies, Novosibirsk

All Listed Sponsors

collaborator

Center for New Medical Technologies, Novosibirsk, Russia

OTHER

lead

S.LAB (SOLOWAYS)

OTHER